Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial.

[1]  C. Cannon,et al.  865-P: Long-Term Ertugliflozin Treatment and Incidence of Hypoglycemia: Analyses from VERTIS CV , 2022, Diabetes.

[2]  E. Huang,et al.  13. Older Adults: Standards of Medical Care in Diabetes-2022. , 2021, Diabetes care.

[3]  C. Cannon,et al.  791-P: Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV , 2021, Diabetes.

[4]  K. Lalić,et al.  AGE AND SEX-BASED DIFFERENCES IN CARDIOVASCULAR OUTCOMES OF SGLT2 INHIBITORS , 2021 .

[5]  A. Scheen.  Careful use to minimize adverse events of oral antidiabetic medications in the elderly , 2021, Expert opinion on pharmacotherapy.

[6]  C. Cannon,et al.  Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial , 2021, Diabetologia.

[7]  C. Cannon,et al.  Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. , 2020, The New England journal of medicine.

[8]  R. Pratley,et al.  Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies , 2020, Diabetes, obesity & metabolism.

[9]  A. Sinclair,et al.  Evaluating glucose‐lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial , 2020, Diabetes, obesity & metabolism.

[10]  Deepak L. Bhatt,et al.  Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study , 2019, Diabetes Care.

[11]  D. DeMets,et al.  Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age , 2019, Circulation.

[12]  B. Zinman,et al.  Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial. , 2019, Age and ageing.

[13]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[14]  C. Cannon,et al.  Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS‐CV) , 2018, American heart journal.

[15]  B. Zinman,et al.  Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. , 2017, The lancet. Diabetes & endocrinology.

[16]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[17]  John M Lachin,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[18]  A. Sinclair,et al.  Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis , 2016, Journal of the American Geriatrics Society.

[19]  J. Coresh,et al.  Kidney Function and Fracture Risk: The Atherosclerosis Risk in Communities (ARIC) Study. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[21]  R. Pratley,et al.  The impact of diabetes and diabetes medications on bone health. , 2015, Endocrine reviews.

[22]  B. Bode,et al.  Long‐term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes , 2015, Diabetes, obesity & metabolism.

[23]  U. Broedl,et al.  Empagliflozin (EMPA) increases genital infections but not Urinary Tract Infections (UTIs) in pooled data from four pivotal phase III trials , 2014 .

[24]  K. Johnsson,et al.  Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. , 2013, Journal of diabetes and its complications.

[25]  Nathaniel Clark,et al.  Diabetes in Older Adults , 2012, Diabetes Care.

[26]  M. Chin,et al.  Prioritization of care in adults with diabetes and comorbidity , 2011, Annals of the New York Academy of Sciences.

[27]  Miguel A Hernán,et al.  The hazards of hazard ratios. , 2010, Epidemiology.

[28]  G. Gambaro,et al.  Treating elderly people with diabetes and stages 3 and 4 chronic kidney disease. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[29]  B. Starfield,et al.  Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. , 2002, Archives of internal medicine.